The latent period between exposure to carcinogen and development of cancer in a given individual can range from a few years to several decades. Even genetically identical mice treated with the same dose of carcinogen under controlled experimental conditions develop tumors after greatly different latent periods. It is, therefore, puzzling why patients that have developed one cancer are at a much increased risk of developing a second cancer within a relatively short time (1-4). One mechanism that might lead to the successive appearance of multiple primary malignancies was suggested by our experimental studies involving the ultraviolet light (UV)1-induced fibrosarcoma, 1591-RE. Like most UV-induced cancers (5), this tumor consists of "potentially malignant," "premalignant," or "regressor" cells that grow in immunodeficient mice but are regularly rejected by normal hosts. In rare instances, heritable variants arise that have lost tumor antigens, and these tumors do grow progressively in normal hosts (6). In the present study, we made a striking and puzzling observation when mice were challenged with the premalignant 1591-RE cells at two anatomically distinct locations. In the rare animals that developed one progressively growing tumor, a second tumor regularly emerged at the other location a short time later. This led us to ask if the development of one tumor could facilitate the outgrowth at another location of a second cancer from premalignant cells. Our results show that indeed this occurs and that the first cancer enhances immunologically the outgrowth of other cancers from premalignant cells.
5010 C; Purina, Inc., St. Louis, MO) and water. The original stock of nude C3H mice was in its 23rd backcross generation when obtained from a colony at the Biology Division of the Oak Ridge National Laboratory. Unless otherwise specified, the abbreviation TBA refers to animals bearing an established progressor tumor >0.7 and <1.2 cm in average diameter (>0.5 and <1.5 cm s in volume).
Fibrosarcoma Lines. The fibrosarcomas 1591-RE, 1316-RE, 2240-RE, 2237-PRO (clone 42), 948-PRO, and 968-PRO were induced in C3H/HeN MTV-mice by repeated exposure to UV light (5) . The fibrosarcomas 1130-RE and 3152-PRO were induced in UV-irradiated C3H/HeN MTV-mice by the subcutaneous injection of 3-methylcholanthrene under the ventral non-UV-exposed skin. Tumors with the postscript "-RE" were strongly immunogenic in that they regressed after an initial 1-2 wk of growth. This phenomenon of regression occurred even when large numbers of the tumor cells (e.g., multiple 1-mm 3 tumor fragments) were injected, although the same tumor inoculum grew and killed nude mice or mice immunosuppressed by x irradiation. Tumors with the postscript "-PRO" grew progressively in (and killed) normal syngeneic mice. Tumors 2237-PRO, 968-PRO, 948-PRO, and 3152-PRO are tumors that grew progressively in normal mice in the first transplant generation. The fibrosarcomas 1591-PRO, 1316-PRO, and 1130-PRO are progressively growing variants of 1591-RE, 13 l 6-RE, and 1130-RE, respectively; these variants arose spontaneously after transplantation of the regressor tumors into normal mice. 1590-PRO has been referred to previously (6) as 1591-PRO. 4 and has lost the "A" antigen while retaining the B antigen (7) . 1591-ASBS is a progressor variant of 1591-RE, sequentially selected in vitro with a cloned anti-A and then anti-B T cell line; this variant lacks the A and the B antigens and has previously been referred to as 1591-V5 (7). K 101-RE is a UV-induced BALB/c fibrosarcoma and P815 is a mastocytoma that spontaneously arose in DBA/2 mice. Using previously described (6) methods tumors were readapted to growth in vitro, expanded in tissue culture within 2 wk of explantation, and cryopreserved in aliquots. Cells were cultured in minimum essential medium containing 10% heat-inactivated fetal bovine serum (CMEM). Whenever tumor cells were required for experiments, frozen aliquots were thawed and used within 48 h. For tumor challenges, solid tumors grown in nude C3H mice were implanted subcutaneously as viable 1-mm 3 fragments with a 13 gauge trocar, or suspensions of cultured cells were injected subcutaneously in 0.2 ml of CMEM. 15 min before surgery mice received 0.5 mg of sodium pentobarbital intraperitoneally. Deep anesthesia was then induced by inhaled ethyl ether and tumors were removed by dissection of their margins.
Generation of Cytotoxic Lymphocytes In Vitro.
Tumor-specific cytotoxic T lymphocytes (CTL) were generated from spleen cells of animals immunized with either three l-ram 3 fragments of solid viable tumor or a single subcutaneous injection of 107 viable cultured tmnor cells. Spleen cells were restimulated in vitro with the immunizing tumor in a mixed lymphocyte-tumor culture (MLTC) as previously described (6) . Alloantigen-specific cytolytic cells were generated by culturing nonimmune C3H/HeN spleen cells for 6 d with 2,000-rad x-irradiated BALB/c spleen cells. Cytotoxicity was determined by the ability of effectors to lyse 5~Cr-labeled target cells during a 6 h assay as previously described (6) . The percentage of specific lysis was calculated by the formula: [(experimental releasespontaneous release)/(total release -spontaneous release)] × 100.
Adoptive Transfer Assay. Lethally (800 tad) x-irradiated mice received, 3-24 h later, spleen cells, intravenously, and tumor fragments, subcutaneously. Spleens were removed from donor mice using sterile techniques, homogenized in a glass tissue grinder, filtered through nylon mesh, centrifuged, and resuspended in CMEM. Recipients received onethird organ equivalents (about 3 × 107 spleen cells) in 0.25 ml CMEM. In some experiments, the spleen cells of the tumor-bearing animals were treated with designated antibodies and complement or complement alone before transfer. Absorbed rabbit complement and monoclonal antibody at approproate concentrations were added to 107 spleen cells in 1 ml CMEM. The mixture was incubated for 30 rain at 37°C, then centrifuged, resuspended, and treated again with the complement and antibody the same way. Monoclonal anti-Thy-1.2 (AT83A) and anti-Ly-2.1 (GS3.168) supernatants (8) (gift of Dr. Frank Fitch, University of Chicago) were used at a dilution of 1 : 10, which eliminates standard control cells. Adherent cells were removed by suspending spleen cells at l0 s cells/ml CMEM into which 200 mg of sterile carbonyl iron particles had been added. The suspension was placed in a 10 cm diam petri dish and incubated 60 rain at 37°C; the iron was then moved to one side with a strong magnet and the remaining nonadherent cells were removed, centrifuged, and washed once in CMEM.
Results

Successive Development of Progressing Tumors at Anatomically Distinct Injection
Sites in the Same Animal. When 100 normal immunocompetent mice were engrafted in both the right and left inguinal regions with the regressor tumor 1591-RE (fifth transplant generation in x-irradiated thymectomized mice), 95 mice rejected both tumor challenges. Curiously, in 5 mice, when progressively growing tumors arose at one of the two engraftment sites, a second progressively growing tumor also developed at the other injection site 2-3 wk later. Probability analysis ~ (9) showed that this phenomenon is incompatible with a model in which the occurrence of a second tumor is independent of the occurrence of the first, suggesting that either the recipient mice showing progressive tumor growth had less immunological resistance than the rest of the mice, or that growth of the first malignancy promoted the growth of the other later-appearing tumor. When the bilateral tumors were individually transplanted into normal mice the tumor that had appeared first always grew out at a higher incidence than the tumor that had emerged later. The comparative second tumors reisolated from each of the into normal mice were 6/12 vs. 1/12, 8/10 same tumors transplanted into nude mice (5/5 vs. 5/5, 4/4 vs. 4/4, and 2/2 vs. 2/2).
tumor incidences for the first and three mice tested and transplanted vs. 4/10, and 5/6 vs. 2/6, while the as controls showed no differences In summary, an average of 68% of first-appearing tumors grew while only 25% of grafts from the later tumors grew in normal mice (P < 0.01), suggesting that the second-appearing tumors were less malignant and possibly more immunogenic than the first-appearing tumor.
The above experiments suggested the possibility that an established tumor may facilitate the growth of a second tumor in the same host. In the following experiments, we therefore determined whether the 1591-PRO tumor would grow faster in mice already carrying an established 1591-PRO tumor at a second site. Thus, 5 x 106 1591-PRO tissue culture cells were injected into normal tumor-free mice or into 1591-PRO TBA. In two independent experiments, the tumor inocula grew significantly faster in the TBA and achieved volumes in 1 mo that were two to six times greater than those in the controls. 3 Thus, animals already bearing a tumor on one site show an enhanced growth of a second tumor transplanted later into the same host at a different site.
Regressor Cells Grew Progressively in Animals Bearing a Progressor Tumor.
The above experiments suggested that an established progressor tumor could facilitate the growth of a second progressor tumor in the same animal. We next determined the strength of this facilitation and its specificity. We analyzed first ,a Assuming that cases of progressive tumor growth are independent of one another, the probability that the second five tumors would emerge in the animals growing the first five tumors is: P = (5 x 4x3x2x 1)/(100 x 99 x 98 x 97 x 96)--1.3x 10 -~. 3 0.99 + 0.14 cm "~ for TBA compared with 0.44 _+ 0.15 cm 3 for controls (7 mice per group); and 1.20 + 0.59 cm ~ for TBA compared with 0.23 +-0.06 cm 3 for controls (5 and 3 mice per group); P < 0.01 in both experiments using Student's t test.
whether the facilitation was strong enough to allow the outgrowth of even highly immunogenic 1591-RE tumor cells. Table I shows that 1591-RE regressor cells indeed developed into progressively growing tumors in most of the 1591-PRObearing mice but failed to grow progressively in normal mice. Since 1591-PRO was derived from 1591-RE and thus belongs to the same tumor lineage, we explored whether regressor tumor cells other than 1591-RE could also be made to grow out in mice bearing 1591-PRO. Table I shows that the 1591-PRO tumor-bearing state did indeed facilitate the outgrowth of two other syngeneic tumors that ordinarily regress; however, 1591-PRO TBA rejected the allogeneic mastocytoma P815.
These experiments showed that 1591-PRO facilitated the outgrowth of several independently derived syngeneic regressor tumors. We next determined (Table  II) whether progressor tumors other than 1591-PRO could also induce such facilitation. We found that this was indeed the case for most progressor tumors whether they had been induced by either UV or MCA or whether the progressor phenotype had been found in the primary isolate or had developed as a variant during subsequent transplant generations. Viewed together, these experiments suggest (a) that facilitation of tumor growth is very strong since it causes the outgrowth of highly immunogenic, potentially malignant cells, and (b) that this facilitation is induced by most independently derived tumors. However, there were certain exceptions to this general rule: For example, 2237-PRO facilitated the outgrowth of both 1591-RE and l l30-RE, while l l30-PRO facilitated growth of 1591-RE but not 1130-RE. Such exceptions will be discussed further below. Also, Table III shows that the progressor tumors must reach a certain volume before they effectively facilitated the outgrowth of a later challenge with regressor cells. However, multiple small tumors that had grown for a short time were as effective as single large tumors that had grown for a longer time. Thus, the size of the burden was more important than the duration of the progressor tumor implant in facilitating the outgrowth of regessor tumor cells. 7/7 (100) 0/14 (0) 0/10 (0) * Three l-ram a regressor tumor fragments were injected subcutaneously into normal mice, nude mice, or mice that had borne 1591-PRO for 3-4 wk (average volume, 0.5 cmS). All tumors were syngeneic, UV-induced regressor fibrosarcomas, with the exception of P815, which is an allogeneic (H-2 d) spontaneous mastocytoma. * Numbers of animals with progressively growing tumors per number challenged (percent in parentheses). Tumor incidence was determined 5 wk after challenge with regressor tumor. All animals that had tumors at 5 wk eventually died because of progressive tumor growth. Data are pooled from four experiments for 1591-RE, three experiments for 1316-RE, two experiments for P815, and one experiment for 2240-RE. § Tumor incidence differs significantly from that in normal mice (P < 0.001). 
Regressor Tumors Growing Out Under the Protection of Progressor Tumors Retain their Highly Immunogenic Regressor Phenotype.
We have previously shown that regressor tumors which upon rare occasions develop into progressively growing tumors in normal animals are always variants that have a heritable loss of an antigen. In contrast, regressor tumors growing out of nude athymic or xirradiated thymectomized mice always retain their tumor-specific antigens (6) . This failure of the latter mice to select for antigen loss variants seems to be a 
.0 5/10 (50) ~ * Mice were engrafted with 1591-PRO at a single site or at three distinct sites. After the indicated duration of growth tile individual tmnors were measured, and then 1591-RE fragments were given to all of the animals. * Number of mice growing 1591-RE per number of mice challenged (percent in parentheses). Tumor incidence assessed 1 mo after challenge. Tumor incidence significantly greater than in mice bearing no progressor tumor (P < 0.05).
Mice were given either 1591-PRO or 3152-PRO. After a period of progressor tumor growth they were challenged with three 1 -ram 3 fragments of 1591-RE. Data are pooled from seven experiments. ! Tumor incidence significantly greater than in mice bearing no progressor tumor (P < 0.01). consequence of their severe immunodeficiency. We analyzed, therefore, the antigenic phenotype of the tumors growing out of progressor tumor-bearing mice in order to assess further the strength of immunoselection exerted by such hosts. Table IV shows that 1591-RE tumors reisolated from 1591-PRO tumorbearing mice after a growth period of at least 4 wk were regularly rejected by normal mice, showing that the reisolated tumors retained the 1591-RE phenotype. To investigate whether these tumors also retained the 1591-RE tumor-specific antigen, we tested the capacity of these tumor cells to restimulate tumor antigen-specific CTL in culture or to serve as targets for such T cells. Table V shows that all the 1591-RE tumors reisolated from TBA could restimulate 1591-RE-specific CTL in culture as effectively as the parental 1591-RE tumor cells, whereas 1591-PRO variants reisolated from normal hosts failed to stimulate. The retention of the target antigen is further demonstrated in Fig. 1 , which shows that 1591-RE tumors reisolated from TBA were as effectively killed by 1591-RE-specific T cells as the 159 I-RE tumor, even when reisolated from TBA bearing an unrelated progressor tumor, the methylcholanthrene (MCA)-induced fibrosarcoma 3152 (Fig. 1, right) . Thus, like severely immunodeficient mice, mice bearing progressively growing tumors neither reject highly immunogenic tumor cells nor select for antigen loss variants.
Regressor Tumors Growing Out Under the Protection of Progressor Tumors Continue to Grow After the Complete Surgical Removal of the Progressor.
Since the progressor tumor was necessary for the outgrowth of the regressor and the regressor retained the regressor phenotype, it seemed reasonable to determine whether surgical removal of the progressor tumor would result in the regression of the immunogenic tumor. Thus, 15 animals were injected with the 1591-PRO tumor and, when the tumors had grown to >0.5 cm 3, the animals were challenged at a second subcutaneous site with a 1591-RE regressor tumor. 2 wk later, the progressor tumor was completely excised surgically. To our surprise, we found in two independent experiments that 15 of 15 1591-RE tumors continued to grow (even five 1591-RE tumors <0.2 cm 3) until the demise of the mice 3-6 wk later. Tumors were removed from three moribund animals; all three retained the regressor phenotype being rejected by normal mice in vivo and remaining sensitive to the tumor-specific cytolytic cells in vitro (data not shown). 
Effector-to-Target Cell Ratio
used as 51Cr-labeled targets for 1591-RE-specific CTL in a 6 h assay. Effector cells were generated in a-standard MLTC using 1591-RE cells for in rive immunization as well as for in vitro restimulation. Identical results were found in a fourth experiment using six additional 1591-RE reisolates (not shown).
,. duced by the growth of the progressor tumor could be transferred by spleen cells. The model we used for these studies was based upon the previous finding (4) that lethally irradiated mice reconstituted with normal unimmunized spleen cells regularly reject a subsequent challenge of a UV-induced regressor tumor. We tested here whether cotransfer of spleen cells from TBA could suppress this T cell-mediated protection. Thus, both lymphocyte populations were injected intravenously into lethally irradiated mice that were then challenged with a progressor tumor. In five experiments (Table VI) , we found that spleen ceils from tumor-bearing animals could completely suppress the resistance to 1591- . Three l-ram 31591 -RE tumors were injected subcutaneously at one site and tumor incidence was measured at 4 wk. Tumor incidence significantly greater in mice receiving both normal and TBA spleen cells than in recipients of only normal spleen cells (P < 0.o01).
RE conferred by normal spleen cells but not that conferred by immune spleen cells. Table VII summarizes further adoptive transfer experiments in which spleen cells from tumor-bearing mice were subjected to various procedures that eliminate different cell types, and then assayed for cells suppressing the tumor rejection capacity of normal spleen cells when cotransferred into irradiated recipients. We found that treatment with anti-Thy-l.2 and complement (C') or with x irradiation (450 tad) eliminated suppression, while treatment with carbonyl iron or with anti-Ly-2.1 and C' did not. The fact that conventional T cells were needed for inducing the suppression is also indicated by the fact that spleen cells from nude TBA fail to cause suppression upon transfer (Table VII , Exps. 8 and 9). As would be expected from our previous results, the suppression mediated by spleen cells of 1591-PRO TBA was not 1591 tumor-specific, since such spleen cells also suppressed the rejection of another UV-induced regressor tumor (data not shown). TBA, however, did not have suppressed responses to nontumor antigens. For example, five animals bearing a 1591-PRO tumor for 1 mo (tumor volume, >1.0 cm 3) were immunized intravenously with 0.2 ml of a 5% (vol/vol) suspension of sheep red blood cells in sterile phosphate-buffered saline, and plaque-forming responses were assayed 4 d later using standard procedures (10). 1591-RE fragments subcutaneously. Tumor incidence was measured 1 mo after challenge. § In cases in which TBA spleen cells were treated with antibody and C', "untreated" "FBA ceils were incubated with C' only. TBA spleen cells received 450 rad of x radiation in vitro immediately before their infusion. Alternatively, a group of mice was reconstituted with 3 x 10 v spleen cells from 1591-RE tumorimmune mice that had received 450 rad in vivo to rule out nonselective radiolysis of spleen cells.
TABLE VII
Phenotype of the Suppressor Cells Isolated from Tumor-bearing Mice
Tumor incidence in group receiving treated TBA spleen cells was significantly less than in group receiving untreated TBA spleen cells (P < 0.05).
The TBA had greater responses than four age-matched, tumor-free control animals (218,273 + 26,000 [SEM] vs. 1 1 1,045 + 15,800) . Unimmunized animals, normal or tmnor bearing, produced no anti-sheep red blood cell plaques. In other experiments (Table VIII) , we found that the proliferative response of spleen cells from TBA to alloantigens was as vigorous as that of normal spleen cells, and that there was no suppression of the cytolytic response to alloantigens (Fig. 2) . This is consistent with our previously mentioned finding (Table I) concerning the normal transplantation resistance of tumor-bearing animals to the allogeneic P815 mastocytoma.
Although TBA are not in a state of generalized immune deficiency, the experiments do not rule out the possibility of a generalized suppression of responses to syngeneic tumor antigens. We therefore carefully examined the specificity of rejection of a syngeneic regressor tumor (e.g., the MCA-induced tumor, 1 130-RE) which, unlike most syngeneic regressor tumors, failed to be suppressed by a given progressor tumor (i.e., 1591-PRO). Mice bearing 1591-PRO were simultaneously engrafted with three tumors: 159 l-RE, 1 130-RE, and a mosaic tumor reisolated from a nude mouse that had been injected with a 1:1 mixture of 1591-RE and 1130-RE cells. Also challenged were 1591-RE-immunized mice that had subsequently received 450 rad of x irradiation; such mice can still reject tumors against which they have previously been immunized but they are incapable of mounting effective rejection responses de novo against other tumors (5). The results (Table IX) show that (a) normal mice rejected all * Spleens were sterilely removed, homogenized with a glass grinder, and suspended in medium consisting of RPMI 1640 supplemented with 5% fetal bovine serum, 0.1 mM MEM nonessential amino acids, 2 mM L-glutamine, 1% penicillin-streptomycin, and 5 X 10 -5 M 2-mercaptoethanol. Stimulator ceils received 2,000 tad of x radiation. Fig. 3 shows that cells reisolated from the tumors emerging from the 1591-PRO TBA challenged with the mosaic tumor were as susceptible to lysis by 1591-RE-specific cytolytic cells as a homogeneous population of 1591-RE control cells. In contrast, cells reisolated from tumors emerging from irradiated 1591-RE-immune mice and challenged with the mosaic were as resistant to lysis as homogenous populations of 1130-RE cells, indicating that only these cells survived. Lysis of control cells reisolated from a nude mouse injected with the mosaic tumor was intermediate (Fig. 3) , indicating that in these mice cells of both tumors survived. Together, the experiments show that TBA do not have a generalized immune suppression to all syngeneic tumors. 4 However, the failure of 1591-PRO TBA to suppress 4 The resistance of the 1130-RE tumor rejection to the suppression in 1591-PRO TBA does not seem to be due to an increased immunogenicity of the 1130-RE tumor as compared with other regressor tumors that are susceptible to this suppression; at least, rejection of 1130-RE is not more resistant to immune suppression by graded doses of x rays than rejection of other regressor tumors. Discussion This study shows that the presence of an established tumor can favor decisively the outgrowth of a second tumor at a different location. This enhancement appears to be a consequence of an immunological suppression caused by the established tumor, since the potentially malignant cells forming the second tumor in the TBA do not normally grow in immunocompetent mice. Furthermore, theta-bearing spleen cells from TBA, but not spleen cells from nude TBA, suppressed tumor rejection by normal spleen cells in adoptive transfer experiments. The suppression was caused by several different progressor tumors and affected the rejection of several different regressor tumors regardless of whether they had been induced by UV radiation. This broad crossreactivity of the described T cell-mediated suppression is in striking contrast to cytolytic and helper T-mediated immunity, which we found to be exceedingly tumor-specific for individual tumors despite extensive testing for crossreactivity (7, i 1, 12 , and unpublished results). The type of suppression described here also appears to be different from another type of tumor-induced immune suppression that affects immune rather than nonimmune T cells and which has specificity for an individual tumor (13) (14) (15) (16) . In many respects, however, the type of suppression we have observed in TBA simulates the suppression caused by UV radiation (5, (17) (18) (19) (20) (21) . and (e) suppresses tumor rejection mounted by naive, unimmunized lymphoid cells but not the protection conferred by lymphoid cells from mice preimmunized to a particular tumor. There are even certain similarities in the exceptions to the crossreactivity of the two types of suppression, such as the failure of the MCAinduced regressor tumor 1 130-RE to be enhanced by UV-induced suppression (22) or by TBA bearing certain progressor tumors. Together, these rather striking similarities suggest that progressively growing tumors and UV irradiation might bring about a similar suppression of the immune system. Indeed, in both cases, the immune system is confronted with a large number of altered cells, and it might be that UV irradiation and neoplastic transformation of cells leads to the expression of gene products that suppress the immune system in a similar way. Consistent with such a notion are experiments showing that transplantation of UV-irradiated skin can suppress tumor rejection (23) . The fact that tumors other than those induced by UV radiation also induce, and are susceptible to, this type of suppression indicates its general relevance to tumor immunology. The tumor-induced immune suppression in the TBA can be even stronger than that induced by UV irradiation, because UV-irradiated hosts still select for antigen loss variants (1 1) while TBA do not. This difference, however, may simply be due to the larger numbers of altered cells to which the TBA is exposed, since the degree of suppression was clearly dependent upon the size of the tumor burden. Thus, only after the first tumor had reached a critical (>0.5 cm s) size was the host's ability to reject highly immunogenic cells abrogated, and the cells were able to develop into a second tumor without undergoing measurable immunoselection by the host. The failure of immune selection was indicated by the fact that these second tumors were rejected regularly upon further transplantation to normal syngeneic hosts at any testable dose of tumor fragments or cells (>1 x 108 cells). The observed strength of suppression and the lack of immunoselection raise the possibility that second primary malignancies in man may be more antigenic than the first cancer and thus may be more susceptible to passive immunotherapy. For active immunotherapy, however, the observed strength and crossreactivity of the immune suppression may well represent a major difficulty. For example, it has been suggested that immunogenic regressor tumor variants obtained after in vitro mutagenesis could be used for active immunotherapy (24, 25) . If our results are generalizable, such an approach is not likely to succeed in tumor-bearing individuals since such regressor variants might both grow out in the patient and even maintain the tumor-induced suppression. We observed that this maintainance of suppression occurred even after the first tumors were completely removed. Furthermore, we found that the second regression tumor continued to grow, even though some of them had reached sizes of only 0.2 cm s or less at the time of removal of the first tumor. This small size might correspond to a size that is clinically undetectable in humans. At present, we do not know how the second (regressor) tumor can maintain the suppression induced by the progressor tumor, but we have recently found that this suppression can be maintained in serial passage through animals bearing only the regressor tumor (C. A. Mullen, unpublished observation). It will be important to learn how to overcome this immune suppression in the tumor-bearing host and to accomplish rejection of these extremely immunogenic tumors after they are well established, since otherwise the outlook for active immunotherapy of other cancers, many of which may be less immunogenic, is poor. One possibility is to develop regimens by which tumor immunity can be generated de novo from the tumor-bearing host's lymphocytes in vitro, followed by adoptive transfer into the tumor-bearing host (26), since we find that T cells from immunized mice are resistant to the suppression.
Several different mechanisms, such as increased genetic susceptibility to cancer development (27) or heavy exposure to carcinogens, may also cause the development of multiple malignancies in the same host; however, our model using genetically inbred mice and cells that have previously encountered a given carcinogen allows us to describe another independent pathway which is mediated by immune suppression. Although the specificity of the described suppression was rather broad, affecting most of the different tumors tested, there was no evidence for a generalized immune suppression in the TBA. The suppression did not affect allograft rejection in vivo, proliferative and cytolytic responses to alloantigens in vitro, nor humoral responses to sheep red blood cells; furthermore, there were exceptional combinations in which a given progressor tumor failed to enhance the outgrowth of a given regressor tumor. For example, TBA growing out 1591-RE still rejected the syngeneic tumor 1130-RE not only at an anatomically distinct site but even admixed within the same (mosaic) tumor.
At present, we can only speculate about which antigens are involved in the crossreactive suppression of tumor-bearing animals. For example, immunosuppressive molecules that are shared by many murine and human tumors such as the P15E protein could be involved (28, 29) . However, we have no evidence for the existence of a single antigen shared between the progressor tumors causing suppression and the suppressed regressor tumors, and it is equally possible that the suppressor T cells do not react with tumor antigen but instead with tumorreactive T cells (30) . The fact that certain tumors are distinct exceptions to the general rule of cross-suppression will help us to separate the observed suppression from other modes of immune suppression and to identify the responsible mechanism.
Summary
We demonstrate that tumor-bearing hosts permit the outgrowth of"potential]y malignant" cells that are located at a different site. These second cancers continued to grow and kill their hosts even though they retain the "premalignant" phenotype, even after removal of the original malignancy. The potentially malignant cells used in these experiments were ultraviolet light-or methylcholanthrene-induced regressor tumor cells that are rejected regularly by normal mice at any testable dose, and only form progressive tumors in immunosuppressed individuals. The immunological rejection of these highly immunogenic, potentially malignant cells was suppressed by Thy-1 +, Ly-2-, nonadherent, radiosensitive suppressor cells in the tumor-bearing mice. These suppressor cells were absent in nude tumor-bearing mice. Unlike helper and cytolytic T cell-mediated responses, which are exquisitely tumor specific, the suppression caused by a progressively growing tumor was crossreactive among many syngeneic, independently derived tumors induced by different carcinogens. However, T cellmediated immune responses to alloantigens, allogeneic tumors, certain syngeneic tumors, and humoral responses to xenogeneic red blood cells were normal in these mice. The immune suppression in the tumor-bearing animals closely simulated that induced by ultraviolet light irradiation, and both types of suppression might therefore share common mechanisms. Our findings may contribute to understanding the growth, development, and possible control of multicentric malignancies and add a precaution to the potential use of strongly immunogenic tumor variants for active immunotherapy in hosts bearing less immunogenic tumors.
